GO
Loading...
Live at 2:30p ET
LINDSEY VONN
CNBC.com web-only interview
Downhill skier Lindsay Vonn

Pharmaceuticals

More

  • Sanofi 2nd quarter profit surges Thursday, 31 Jul 2014 | 3:02 AM ET

    PARIS— French drug maker Sanofi said Thursday its earnings soared in the second quarter thanks to lower accounting charges than a year earlier, and the company lifted it full-year profit forecast.

  • LONDON, July 31- AstraZeneca smashed forecasts for second-quarter sales and earnings on Thursday, demonstrating resilience after seeing off a $118 billion takeover approach from rival drugmaker Pfizer two months ago.

  • PARIS, July 31- French drugmaker Sanofi raised its full-year profit forecast on Thursday along with a set of stronger than expected quarterly earnings driven by its rare disease and diabetes businesses and higher sales in emerging markets.

  • LONDON, July 31- AstraZeneca smashed forecasts for second-quarter sales and earnings on Thursday, demonstrating resilience after seeing off a $118 billion takeover approach from rival drugmaker Pfizer two months ago.

  • July 30- Israeli drugmaker Teva Pharmaceuticals Industries said on Wednesday it turned back efforts by Israeli industrialist Benny Landa to shake up the company's board of directors, with shareholders approving all of the company's proposals and board nominations.

  • *Sanofi to file drug for US and EU approval by year-end. PARIS, July 30- A new drug being developed by French drugmaker Sanofi and U.S. partner Regeneron cut "bad" LDL cholesterol more than placebo and existing treatments in nine late-stage clinical trials, the companies said on Wednesday.

  • Hospira beats profit estimates, raises 2014 outlook Wednesday, 30 Jul 2014 | 7:58 AM ET

    July 30- Hospira Inc, a pharmaceutical and medical device maker, posted a better-than-expected quarterly profit on higher sales of specialty injectable drugs, and raised its full-year outlook.

  • Euro dampened Bayer's profits: CEO     Wednesday, 30 Jul 2014 | 5:10 AM ET

    Marijn Dekkers, CEO of Bayer, says that operationally, the group had a "very good quarter", but that profits were dampened by the strength of the euro.

  • Key witness testifies in ex-governor's trial Wednesday, 30 Jul 2014 | 4:57 AM ET

    RICHMOND, Va.— When former Virginia Gov. Bob McDonnell and his wife, Maureen, were indicted on corruption charges in January, the couple stood together at a hastily called news conference to denounce the charges.

  • Biotech drugmaker Amgen laying off at least 2,400 Tuesday, 29 Jul 2014 | 4:04 PM ET

    Biologic drugmaker Amgen said Tuesday that it will lay off 12 to 15 percent of its worldwide workforce and close four sites, even as it reported stellar second-quarter results that trounced Wall Street expectations. Amgen also raised its forecasts for its 2014 profit and revenue, driving up its shares.

  • UPS CFO Kurt Kuehn on UPS settlement     Tuesday, 29 Jul 2014 | 4:00 PM ET

    UPS CFO Kurt Kuehn on CNBC's Squawk on the Street on his company's decision to stop deliveries for illegal online pharmacies and pay $40 million to end a Federal criminal probe into its shipping practices. Rival FedEx was in court today fighting similar charges.

  • Pharma CEOs: Tax system flaws help overseas rivals Tuesday, 29 Jul 2014 | 1:35 PM ET
    Ian Read, CEO, Pfizer,  leaves the House of Commons on May 14, 2014 in London.

    Pfizer CEO Ian Read also says a potential U.S. tax holiday would be only a temporary solution.

  • *FDA lists 10 violations at Taiwan plant. July 29- Impax Laboratories Inc said the U.S. Food and Drug Administration raised concerns about the company's factory in Taiwan, casting in doubt the future of its Parkinson's drug, rytary.

  • Merck & Pfizer beat the Street     Tuesday, 29 Jul 2014 | 10:14 AM ET

    CNBC's Meg Tirrell reports both Merck and Pfizer beat earnings expectations amid patent expirations.

  • July 29- Impax Laboratories Inc said the U.S. Food and Drug Administration issued certain observations regarding violations in the company's manufacturing plant in Taiwan. Shares of Impax, which makes generics and specialty drugs to treat central nervous system disorders, fell about 17 percent to $23.15 premarket on Tuesday.

  • July 29- Merck& Co Inc reported better-than-expected quarterly results on Tuesday, with sales of consumer products and medicines for arthritis and HIV helping to offset the impact of generic competition on other drug sales. Merck, the No. 2 U.S. drugmaker, earned $2.03 billion, or 68 cents per share, in the second quarter.

  • Big pharma tax attack     Tuesday, 29 Jul 2014 | 8:04 AM ET

    Fundamentally, U.S.-based companies are at a disadvantage because of our tax code, says Barbara Ryan, FTI Consulting, sharing her thoughts on tax inversion among the big pharma space.

  • Big pharma by the numbers     Tuesday, 29 Jul 2014 | 8:02 AM ET

    What we are seeing is innovation is not dead, says Barbara Ryan, FTI Consulting, discussing Pfizer and Merck's second quarter results and big Pharma drug trends.

  • Pfizer's 2Q profit sinks 79 pct but tops forecasts Tuesday, 29 Jul 2014 | 7:37 AM ET

    Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a $10 billion- plus gain from a business spinoff.

  • Pfizer to renew AstraZeneca bid?     Tuesday, 29 Jul 2014 | 5:50 AM ET

    Ranjith Gopinathan, programme manager, life sciences and healthcare practice at Frost & Sullivan, discusses pharmaceutical groups Merck and Pfizer ahead of their quarterly results.